FDA approves new larger production setup for Genmab drug

After the US health authorities approved a new production setup at Horizon Therapeutics, which holds the rights to Genmab's drug Tepezza, the company expects that current supply-related issues will soon be resolved.
Photo: PR / Genmab
Photo: PR / Genmab
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

With April 1 as the starting point, Horizon Therapeutics expects to put a stop to the supply issues which have affected the company's new and highly popular launch Tepezza since December last year, which the firm states in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading